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ABSTRACT 
Objective: A trial was conducted in Burkina Faso and Mali to investigate whether addition of azithromycin 
to the antimalarials used for seasonal malaria chemoprevention reduces mortality and hospital 
admissions of children. We tested the sensitivity of nasal isolates of Streptococcus pneumoniae obtained 
during this trial to azithromycin and other antibiotics. 
Methods: Azithromycin or placebo was administered monthly, in combination with the antimalarials used 
for seasonal malaria chemoprevention, for four months, over the annual malaria transmission seasons of 
2014, 2015 and 2016. Nasopharyngeal swabs were collected from 2773 Burkinabe and 2709 Malian 
children on seven occasions: in July and December each year prior to and after drug administration, and 
at a final survey in early 2018. Pneumococci were isolated from nasopharyngeal swabs and tested for 
sensitivity to azithromycin and other antibiotics.
Results: 5482 samples were collected. In Burkina Faso, the percentage of pneumococcal isolates resistant 
to azithromycin among children who had received it increased from 4.9% (95% CI: 2.4%, 9.9%) before the 
intervention to 25.6% (95% CI: 17.6%, 35.7%) afterwards. In Mali the increase was from 7.6% (95% CI: 
3.8%, 14.4%) to 68.5% (95% CI: 55.1%, 79.4%). The percentage of resistant isolates remained elevated 
(17.7% (95% CI: 11.1%, 27.1%) in Burkina Faso and 19.1% (95% CI: 13.5%, 26.3%) in Mali) among children 
who had received azithromycin one year after stopping the intervention. An increase in resistance to 
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Conclusion: Addition of azithromycin to the antimalarial combination used for seasonal malaria 
chemoprevention was associated with an increase in resistance of pneumococci to azithromycin and 
erythromycin, which persisted one year after the last administration of azithromycin.  
Keywords: Pneumococcal carriage, Azithromycin, Resistance, Sub-Saharan Africa
INTRODUCTION 
In Burkina Faso and Mali, malaria continues to be a burden with a large number of cases and high 
mortality rates despite control efforts. In 2016, WHO estimated 7.9 million malaria cases with 21,300 
fatalities in Burkina Faso and 7.2 million cases with 12,400 fatalities in Mali [1]. Malaria is highly seasonal; 
60% to 80% of cases occur during the raining season in both countries.
Mass drug administration (MDA) with azithromycin (AZ) is being widely deployed as a highly effective 
method for the control of trachoma [2]. The incidence of respiratory, gastrointestinal and skin infections 
and malaria [3-8] is lower in children who participated in mass AZ campaigns. An additional, surprising 
finding was detection of a more than 50% reduction in mortality in children who participated in an AZ 
MDA programme in Ethiopia, a reduction that was sustained over a period of 26 months [9, 10]. This 
unexpected finding led to the MORDOR (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la 
Résistance) trial, which investigated the impact of two rounds of AZ MDA on mortality in children under 
the age of five years in Malawi, Niger and Tanzania [11]. An overall reduction in mortality of 13.5 % was 
observed, with the reduction being most marked in Niger and in children under the age of one year.
On the basis of the findings of the study in Ethiopia, we hypothesised that adding AZ to the 
antimalarial combination sulphadoxine-pyrimethamine and amodiaquine (SP+AQ) used for seasonal 
malaria chemoprevention (SMC) would further reduce child mortality and severe morbidity, and we 
conducted a trial in 19,200 children aged 3 to 59 months in Burkina Faso and Mali to investigate this 
hypothesis. Modest reductions in the incidence of gastrointestinal, respiratory tract and skin infections 
and non-malaria fevers were seen, but the addition of AZ to the antimalarial used for SMC had no impact 
on child mortality or hospital admissions [12]. 
A concern over the use of AZ for MDA programs is that this will enhance resistance to macrolide 
antibiotics. An increase in the resistance of Streptococcus pneumoniae to AZ has been observed in several 
MDA studies, although this has often been only short-term [5, 13-19]. An increase in resistance of 
Staphylococcus aureus to AZ after MDA for trachoma control has also been reported [20]. For these 
reasons the antibiotic sensitivity of nasopharyngeal isolates of S. pneumoniae was studied during the SMC 
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METHODS 
Design and conduct of the SMC + AZ trial
Details of the trial in Burkina Faso and Mali to investigate the impact of adding AZ to the antimalarial 
drugs used for SMC have been published previously[12]. In brief, 19,200 children aged 3-59 months were 
randomised to receive SP and AQ with either AZ or placebo. Randomisation was by household. Infants 
aged 3-11 months received SP 250 mg/12.5 mg and AQ 75 mg on day 1 and AQ 75 mg on days 2 and 3. In 
addition, they received AZ 100 mg or matching AZ placebo on days 1, 2, and 3. Children aged 1-4 years 
received double these doses. SP+AQ was supplied by Guilin Pharmaceutical (Shanghai, China), and AZ and 
matching placebo were supplied by CIPLA (Mumbai, India). All doses of treatments were given by trial 
staff. Coverage with the monthly treatments was high, with more than 80% of children receiving three or 
four rounds of treatment each year. Deaths, hospital admissions and attendances at clinics were recorded 
throughout the study period as described earlier [12]. Cross-sectional surveys were undertaken at the end 
of each malaria transmission season. The overall outline of the study is shown in supplementary Figure S1.
Nasopharyngeal carriage surveys
Nasopharyngeal swabs were collected from 2773 Burkinabe and 2709 Malian children at cross-sectional 
surveys at seven time points. Children were randomly selected by an independent statistician, with a new 
sample drawn for each time point. Swabs were collected in July 2014, 2015 and 2016 just before the first 
round of AZ or placebo was given and in December of each of these years 4-6 weeks after the last round 
of AZ or placebo had been given (hereafter referred to as pre- and post-2014 etc.). Swab samples were 
also taken early in 2018, one year after the last administration of AZ or placebo. 
Randomized children were gathered in a health facility and trained staff took samples on-site while 
completing the required documents. A sample was taken from the posterior wall of the child’s 
nasopharynx using a calcium alginate swab (FLOQSwabs, Copan Diagnostics Inc. Murrieta, CA, USA) and 
immediately transferred to a cryotube containing skimmed milk-tryptone-glucose-glycerol medium 
(STGG). The cryotubes were labelled and placed in a cold box prior to transfer to the laboratory within 
eight hours of collection and stored at -80° C until analysed [21, 22].
Laboratory methods 
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Statistical analysis
The primary study endpoint was the prevalence of nasal carriage isolates of S. pneumoniae resistant to AZ 
at the seven time points described above. A secondary end-point was the overall prevalence of 
pneumococcal carriage in the two intervention groups at the same time points. Exploratory endpoints 
included the analysis of the sensitivity of pneumococci to other antibiotics.
Sample size
A sample size of 400 children per survey per country was chosen for the nasopharyngeal sub-study on the 
basis that the pneumococcal carriage prevalence would be 50%, and thus 200 samples would be positive 
and available for resistance assays at each survey in each country. Assuming that the prevalence of 
resistance was 50% among the 200 samples available for resistance assays, the precision of the estimate 
of resistance for each country, at each time point, would be within 15% of the true value.
Trial oversight
The trial was approved by ethics committees of the London School of Hygiene & Tropical Medicine, of the 
Malaria Research and Training Centre, Bamako, and of the Ministry of Health in Ouagadougou. The trial 
was also approved by the national regulatory authorities in Burkina Faso and Mali, and registered on 
Clinicaltrials.gov (NCT02211729). 
Written consent was obtained from parents or guardians for inclusion of a child in the overall trial 
and further consent was obtained from parents or guardians of children selected for the pneumococcal 
carriage sub-study. A data safety monitoring board reviewed serious adverse events and monitored the 
trial’s overall progress. An international steering committee reviewed the protocol and provided advice 
throughout the course of the study. 
RESULTS
Study population and samples 
A total of 5482 nasopharyngeal specimens were collected, 2773 from children in Houndé, Burkina Faso 
(1379 from the AZ and 1394 from the placebo group) and 2709 from children in Bougouni, Mali (1346 
from the AZ and 1363 from the placebo group). Sex and age distribution of study children were well 
balanced between the AZ and placebo groups, and the prevalence of pneumococcal carriage was 
comparable in each group at baseline in both countries (Tables 1 and 2). The numbers of swabs obtained 
at each survey and tested for antibiotic resistance are shown in Tables 3 and 4. 
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was reported by 4.1% to 14.6% of children in Burkina Faso and by 6.9% to 11.9% of children in Mali in 
different surveys (Table 1). Antibiotic use among the subset of children with a recent morbidity episode 
was higher, often exceeding 50%. Amoxicillin was the most commonly prescribed antibiotic, accounting 
for 120 of the 140 (85.7%) reported antibiotic treatments of participants in Burkina Faso and for 112 of 
180 (62.2%) treatments in Mali. Erythromycin (10.0% of antibiotic treatments), co-trimoxazole (10.6%) 
and metronidazole (21.7%) were also commonly used in Mali.
Pneumococcal conjugate (PCV13) vaccination was introduced into the Expanded Programme of 
Immunization in 2013 in Burkina Faso and in 2011 in Mali. Vaccination cards were often not available at 
the time of the annual census of all children in the trial. Vaccine coverage with PCV13 in Burkina Faso 
among children whose vaccine status was known was 58.3% when first measured before the 2015 malaria 
transmission season, but improved substantially in 2016 (Table 1). In Mali, PCV vaccine coverage was 
>90% at all survey contacts. 
Prevalence of nasopharyngeal carriage of Streptococcus pneumoniae
The overall prevalence of nasopharyngeal carriage of S. pneumoniae at baseline was 67.4% in Burkina 
Faso and 63.5% in Mali (Tables 1 and 2; Figures 1a and 1b). Overall carriage remained >50% at the five 
subsequent surveys during the study period, with the exception of the post-2016 survey, when overall 
carriage was 46.7% in Burkina Faso and 40.4% in Mali. Carriage was generally lower in the AZ group in 
Burkina Faso but differences between the two study groups were not marked, with overlapping 
confidence intervals, apart from two occasions when prevalence was significantly lower in the AZ group: 
post-2014 in Burkina Faso, with a prevalence ratio (PR) of 0.79 (0.68, 0.92; P=0.003) and post-2016 in Mali 
(PR 0.62 (0.47, 0.80), P<0.001). 
One year after the last administration of SMC with AZ, the prevalence of pneumococcal carriage was 
60.0% in Burkina Faso (Table 1 and Figure 1a), and slightly lower in the group that had previously received 
AZ than in the placebo group (PR 0.86 (0.73, 1.03); P=0.095). In Mali, the prevalence of pneumococcal 
carriage was 88.3% one year after the last administration of SMC with AZ (Table 2 and Figure 1b), again 
slightly but not markedly lower in the group that received AZ (PR 0.94 (0.88, 1.01); P=0.096). Because of 
the unexpectedly high isolation rate in the last survey conducted in Mali, these samples were retested 
and a high isolation rate was confirmed (Supplementary Table S1). 
Resistance of pharyngeal isolates of Streptococcus pneumonia to azithromycin
At baseline, the overall prevalence of resistance to AZ among nasopharyngeal isolates of S. pneumoniae 
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Burkina Faso, the prevalence of AZ resistance at baseline was 3.1% using the E-test (Figures 2a and 2b). In 
Mali, the E-test was used only to confirm resistance in positive samples identified by the disc diffusion 
assay and, at baseline, only two samples were tested, both of which were positive with each assay. 
In Burkina Faso, results obtained using the disc diffusion assay showed that the prevalence of 
resistance to AZ increased over time in both study groups, reaching approximately 10% or more from the 
post-2015 survey onwards. Prevalence was higher in the AZ group at each of the first 6 surveys, apart 
from the pre-2016 survey, although differences were only marked at two time points: post-2014 and post-
2016 (PR 2.29 (0.98, 5.37), (P=0.056) and PR 1.95 (1.05, 3.61), (P=0.034), respectively). One year after the 
last administration of AZ or placebo the prevalence of resistance was markedly higher than the prevalence 
seen at baseline: 16.2% in the placebo group and 17.7% in the AZ group. Similar results were obtained 
with the AZ E-test (Oxoid Ltd, England), although due to a shortage of test strips in 2016, not all samples 
positive for carriage could be tested at the pre-2016 and post-2016 surveys.
In Mali, the prevalence of AZ resistance according to the disc diffusion assay increased relative to 
baseline but remained below 10% in 2014 and 2015. Prevalence of AZ resistance exceeded 20% in both 
groups at both the pre-2016 and post-2016 surveys, and was markedly higher in the AZ group at the post-
2016 survey: PR 2.22 (1.51, 3.27); P<0.001). At the first four surveys (pre-2014 to post-2015), all samples 
positive by disc assay were confirmed positive by E-test; approximately two-thirds of samples positive by 
disc assay were confirmed to be positive by E-test at the 2016 surveys. Because of the very high level of 
resistance to AZ found in the post-2016 survey, these samples were retested and a high level of 
concordance between the two sets of testing was found (Supplementary Table S2). 
Analysis of changes in the pattern of resistance to AZ over time by age group did not show any age 
effect in either Burkina Faso or Mali (Supplementary Figure S2). 
Resistance of pharyngeal isolates of S. pneumoniae to erythromycin
Resistance to erythromycin, assessed with a disc diffusion assay, showed a very similar pattern to that 
seen for AZ (Supplementary Figures S3 and S4). In Burkina Faso, the prevalence of resistance increased 
from a prevalence at baseline of 3.5%, exceeding approximately 10% at all time points after the post-2015 
survey. Prevalence of resistance was higher in the AZ than in the placebo group at all but one survey, but 
there was only weak statistical evidence of a true difference on two occasions: PR 1.73 (1.00, 2.99; 
P=0.049) at the post-2015 survey, and PR 1.86 (1.00, 3.47; P=0.051) at the post-2016 survey. There was no 
evidence of a difference persisting between the groups at the 2018 survey.
In Mali, the results for erythromycin also closely mirrored those obtained for AZ: there was a 
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onwards the overall prevalence of resistance exceeded 10%. Prevalence was higher in the AZ group at all 
but one time point, with evidence of a true difference between the study groups in the post-2015 survey 
(PR 3.20 (1.06, 9.65; P=0.039) and strong evidence of a true difference at the post-2016 survey (PR 2.33 
(1.54, 3.51; P<0.001). At the 2018 survey, the prevalence of erythromycin resistance had dropped below 
17% in both study groups and there was no evidence of a difference between groups.
Resistance of pharyngeal isolates of S. pneumoniae to penicillin
In Burkina Faso, the E-test was used to determine sensitivity to penicillin. The overall prevalence of 
resistance at the first survey was 13.5%; during the remainder of the study period this ranged between a 
low of 5.1% at the pre-2015 survey and a high of 22.5% at the post-2015 survey, with no evidence of any 
difference between the study groups (Table 5). At the 2018 survey, the overall prevalence was 25.8%, 
again with no difference between study groups (PR 1.09 (0.69, 1.73; P=0.71). 
Resistance of pharyngeal isolates of S. pneumoniae to other antibiotics
Resistance to ceftriaxone, norfloxacin and vancomycin was measured only in isolates obtained in Burkina 
Faso. Overall, a very low prevalence of resistance to ceftriaxone was found using either a disc diffusion 
method or an E-test over the whole study period (0.61% and 0.31% respectively). Resistance to 
norfloxacin, tested with a disc diffusion test, was slightly more frequent and found in 85 samples (5.3% of 
those tested) over the study period, ranging from 11 positives (3.8% of those tested) at baseline to a low 
prevalence at the end of the study period, with only 1 positive at the post-2016 survey and 3 positives at 
the 2018 survey. No resistance to vancomycin was found in any of the 1633 isolates tested. 
DISCUSSION
This study evaluated the impact of AZ, combined with SMC, given once a month for 4 months (August to 
November) over a three-year period (2014-2016) on the resistance of S. pneumoniae to AZ. This was a 
more intense treatment schedule than that used in previous MDA studies employing AZ for control of 
trachoma [7, 8, 13-20, 23]. The two regions of Houndé in Burkina Faso and Bougouni in Mali had received 
the last distribution of AZ) (Zithromax) for control of trachoma in 2007 and 2011 respectively, and this is, 
therefore, unlikely to have affected the results of this study [24].
The overall prevalence of carriage of S. pneumoniae declined modestly over time in children who had 
received either AZ or placebo with the exception of an unexpected increase in the 2018 survey in Mali; 
this increase was confirmed on retesting so is likely to be a true, but unexplained, finding. Carriage tended 
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Burkina Faso and post-2016 in Mali), differences were not large and may have been due to chance.
In both Burkina Faso and Mali, resistance of pharyngeal isolates of S. pneumoniae to AZ and 
erythromycin increased substantially during the course of the study and this persisted for a year after the 
last drug administration. This contrasts with the findings in most other studies in which the prevalence of 
resistance has usually returned close to baseline at surveys some months after the last drug 
administration[16, 18]. There was strong statistical evidence of a difference between the AZ and placebo 
groups only at the post-2015 survey in Burkina Faso, and at the post-2016 survey in Mali. Although study 
children were randomised by household, rather than individually, there may have been sufficient mixing 
between young children in neighbouring households to dilute differences between the intervention 
groups; a cluster-randomised village trial might have found more marked differences between study 
groups. As expected, patterns of resistance to erythromycin matched those seen for AZ. A modest level of 
resistance to penicillin, as assessed by the E-test, was found but resistance to other antibiotics tested was 
rare. 
Incorporation of AZ into the SMC treatment regimen did not have any significant impact on deaths or 
hospital admission due to non-traumatic causes but addition of AZ did reduced the incidence of visits to a 
health facility or community health worker due to an acute respiratory tract, gastrointestinal or skin 
infection and of non-malaria fever by about 20% [11]. These gains will need to be balanced against the 
costs of adding AZ to the SMC regimen, currently being assessed, and against the risk of inducing 
widespread resistance of S. pneumoniae, and perhaps other bacterial pathogens, including gastro-
intestinal pathogens, to macrolide antibiotics. Erythromycin and (particularly) AZ are currently used 
infrequently for treatment of young children at government-supported clinics in the study areas, but they 
may be prescribed more frequently in pharmacies and private clinics and their loss to the list of effective 
and affordable antibiotics would be a significant one. 
This study has some weaknesses. Although efforts were made to standardise laboratory procedures 
in Burkina Faso and Mali, some differences in methods emerged, in part because of difficulties in 
obtaining reagents at the appropriate time. Hence, it was decided to undertake separate analyses in each 
country rather than merging the data. Nevertheless, very similar results were found in each country. In 
addition, data on coverage with pneumococcal conjugate vaccine were not recorded for each study 
participant, but the information that was available indicates that a high proportion had received at least 
one dose of this vaccine.
Policy makers are currently considering the potential of widespread deployment of AZ mass drug 
administration as an infant survival strategy in countries where infant mortality remains high. The results 
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pathogens will need to be taken into consideration when policy decisions are being made on the costs and 
benefits of this intervention. 
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Table 1.  General characteristics of children in the two study groups (Burkina Faso) 
 















 SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ 
Total children (n) 213 217 213 205 196 205 197 191 192 193 201 195 182 173 
Male %          (n) 53.1 (112) 47.5 (103) 50.2 (107) 47.3 (97) 53.1 (104) 55.1 (113) 50.3 (99) 45.0 (86) 54.2 (104) 54.9 (106) 50.75 (102) 53.9 (105) 52.8 (96) 53.8  (93) 
Age               
< 12 months 21.6 (46) 24.0 (52) 11.3 (24) 10.2 (21) 15.8 (31) 12.7 (26) 7.6 (15) 8.9 (17) 16.7 (32) 13.0 (25) 8.0 (16) 8.7 (17) 0.0 (0) 0.0 (0) 
12-23 months 17.4 (37) 17.5 (38) 20.7 (44) 20.5 (42) 15.3 (30) 25.9 (53) 25.4 (50) 20.9 (40) 16.2 (31) 24.4 (47) 24.9 (50) 26.2 (51) 0.0 (0) 0.0 (0) 
24-35 months 23.0 (49) 23.5 (51) 21.1 (45) 21.5 (44) 24.0 (47) 20.0 (41) 22.3 (44) 23.6 (45) 22.9 (44) 22.3 (43) 19.4 (39) 21.5 (42) 20.3 (37) 20.2 (35) 
36-47 months 19.7 (42) 16.6 (36) 21.1 (45) 20.0 (41) 22.4 (44) 21.5 (44) 20.8 (41) 25.7 (49) 25.0 (48) 19.2 (37) 20.4 (41) 14.4 (28) 18.7 (34) 20.2 (35) 
48 months + 18.3 (39) 18.4 (40) 25.8 (55) 27.8 (57) 22.4 (44) 20.0 (41) 23.9 (47) 20.9 (40) 19.3 (37) 21.2 (41) 27.4 (55) 29.2 (57) 61.0 (111)* 59.5 (103)* 
               
PCV vaccination % (n) NA NA NA NA 64.2 (43) 52.3 (34) 57.9 (33) 71.2 (42) 95.2 (99) 89.4 (93) 87.0 (87) 87.0 (80) NA NA 
n missing  NA NA NA NA 129 140 140 132 88 89 101 103 NA NA 
Recent antibiotic use % (n) NA NA 6.10 (13) 5.85 (12) 8.67 (17) 14.6 (30) 6.60 (13) 6.28 (12) 6.77 (13) 6.74 (13) 4.48 (9) 4.10 (8) NA NA 
Number with recent illness  NA NA 20 18 43 50 19 19 32 38 16 12 NA NA 
Antibiotic use if recent 
illness % (n) 
NA NA 65.0 (13) 66.7 (12) 39.5 (17) 60.0 (30) 68.4 (13) 63.2 (12) 40.6 (13) 34.2 (13) 56.3 (9) 66.7 (8) NA NA 
Pneumococcal carriage % (n) 69.0 (147) 65.9 (143) 69.5 (148) 55.1 
(113) 
57.7 (113) 50.2 (103) 72.6 (143) 64.9 (124) 53.7 (103) 49.7 (96) 49.3 (99)  44.1 (86) 64.3 (117) 55.5 (96) 
Prevalence Ratio (95% CI) 0.95 (0.84, 1.09) 0.79 (0.68, 0.92) 0.87 (0.73, 1.05) 0.89 (0.78, 1.02) 0.93 (0.76, 1.12) 0.90 (0.72, 1.11) 0.86 (0.73, 1.03) 
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Notes: SMC+P = seasonal malaria chemoprevention with placebo; SMC+AZ = seasonal malaria chemoprevention with azithromycin; PCV = pneumococcal 
conjugate vaccine. *In 2018 survey the age category “48 months +” includes children up to six years of age due to this survey being conducted one year 
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Table 2. General characteristics of children in the two study groups (Mali) 
 















 SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ SMC+P SMC+AZ 
Total children (n) 174 168 203 204 205 194 197 198 190 191 187 198 207 193 
Male %         (n) 53.5 (93) 54.8 (92) 50.3 (102) 51.0 (104) 50.2 (103) 48.5 (94) 45.2 (89) 57.1 (113) 56.3 (107) 50.3 (96) 45.5 (85) 60.1  (119) 47.3 (98) 59.1 (114) 
Age               
< 12 months 13.8 (24) 11.3 (19) 10.8 (22) 11.8 (24) 11.7 (24) 12.9 (25) 7.6 (15) 11.6 (23) 13.7 (26) 12.6 (24) 9.6 (18) 9.1 (18) 0 (0.0) 0 (0.0) 
12-23 months 18.4 (32) 22.6 (38) 21.2 (43) 20.6 (42) 20.5 (42) 24.2 (47) 18.3 (36) 16.2 (32) 17.4 (33) 25.7 (49) 19.8 (37) 21.2 (42) 5.3 (11) 5.7 (11) 
24-35 months 21.3 (37) 19.6 (33) 22.2 (45) 21.1 (43) 19.5 (40) 20.6 (40) 23.4 (46) 24.2 (48) 24.7 (47) 17.3 (33) 23.0 (43) 23.7 (47) 22.7 (47) 21.2 (41) 
36-47 months 27.0 (47) 23.2 (39) 23.6 (48) 23.0 (47) 24.9 (51) 19.6 (38) 22.3 (44) 21.7 (43) 24.2 (46) 22.0 (42) 21.9 (41) 21.7 (43) 21.7 (45) 21.2 (41) 
48 months + 19.5 (34) 23.2 (39) 22.2 (45) 23.5 (48) 23.4 (48) 22.7 (44) 28.4 (56) 26.3 (52) 20.0 (38) 22.5 (43) 25.7 (48) 24.2 (48) 50.2 (104)* 51.8 (100)* 
               




95.8 (158) NA NA 
n missing  NA NA NA NA 46 55 45 38 29 22 26 33 NA NA 
Recent antibiotic use % (n) NA NA 9.85 (20) 6.86 (14) 9.76 (20) 11.9 (23) 9.64 (19) 8.08 (16) 7.37 (14) 7.85 (15) 10.2 (19) 10.1 (20) NA NA 
Number with recent illness  NA NA 30 25 42 47 31 36 60 54 33 36 NA NA 
Antibiotic use if recent illness % 
(n) 
0.0 (0) 0.0 (0) 66.7 (20) 56.0 (14) 47.6 (50) 48.9 (23) 61.3 (19) 44.4 (16) 23.3 (14) 27.8 (15) 57.6 (19) 55.6 (20) NA NA 
Pneumococcal carriage % (n) 63.2 
(110) 
63.7 (107) 56.2 (114) 58.8 (120) 53.7 (110) 56.7 (110) 72.6 (143) 67.7 (134) 25.8 (49) 28.3 (54) 50.3 (94) 31.0 (61) 90.8 (188) 85.5 (165) 
Prevalence Ratio (95% CI) 1.01 (0.85, 1.19) 1.05 (0.89, 1.24) 1.06 (0.88, 1.27) 0.93 (0.82, 1.06) 1.10 (0.79, 1.53) 0.62 (0.47, 0.80) 0.94 (0.88, 1.01) 
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Notes: SMC+P = seasonal malaria chemoprevention with placebo; SMC+AZ = seasonal malaria chemoprevention with azithromycin; PCV = pneumococcal 
conjugate vaccine. *In 2018 survey the age category “48 months +” includes children up to six years of age due to this survey being conducted one year 





Table 3. The prevalence of azithromycin (AZ) and erythromycin (ERY) resistance in nasopharyngeal isolates of Streptococcus pneumoniae in Burkina Faso 
     SMC + Placebo SMC + Azithromycin   




















Azithromycin Pre-2014 147 147 3 2.04 143 143 7 4.90 2.40 (0.63, 9.13) 0.199 
disc assay Post-2014 148 148 8 5.41 113 113 14 12.4 2.29 (0.98, 5.37) 0.056 
 Pre-2015 113 113 5 4.42 103 103 8 7.77 1.76 (0.59, 5.21) 0.311 
 Post-2015 143 143 19 13.3 124 124 25 20.2 1.52 (0.88, 2.62) 0.134 
 Pre-2016 103 103 11 10.7 96 96 9 9.38 0.88 (0.38, 2.03) 0.761 
 Post-2016 99 99 13 13.1 86 86 22 25.6 1.95 (1.05, 3.61) 0.034 
 2018 117 117 19 16.2 96 96 17 17.7 1.09 (0.59, 2.03) 0.785 
Azithromycin Pre-2014 147 147 4 2.72 143 143 5 3.50 1.28 (0.35, 4.71) 0.705 
E-test Post-2014 148 148 8 5.41 113 113 15 13.3 2.46 (1.06, 5.68) 0.036 
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 Post-2015 143 143 22 15.9 124 124 30 24.2 1.57 (0.96, 2.58) 0.073 
 Pre-2016* 103 12 11 91.7* 96 9 9 100* NA  
 Post-2016* 99 67 18 26.9* 86 67 30 44.8* NA  
 2018 117 117 21 17.9 96 96 18 18.8 1.04 (0.58, 1.88) 0.884 
Erythromycin Pre-2014 147 147 3 2.04 143 143 7 4.90 2.40 (0.63, 9.13) 0.199 
disc assay Post-2014 148 148 8 5.41 113 113 14 12.4 2.29 (0.98, 5.37) 0.056 
 Pre-2015 113 113 5 4.42 103 103 8 7.77 1.76 (0.59, 5.21) 0.311 
 Post-2015 143 143 18 12.6 124 124 27 21.8 1.73 (1.00, 2.99) 0.049 
 Pre-2016 103 103 11 10.7 96 96 9 9.38 0.88 (0.38, 2.03) 0.761 
 Post-2016 99 99 13 13.1 86 86 21 24.4 1.86 (1.00, 3.47) 0.051 
 2018 117 117 17 14.5 96 96 17 17.7 1.22 (0.64, 2.32) 0.548 
 
* In 2016 the azithromycin E-test was used only to confirm samples positive by the azithromycin disc assay, not to test all samples. Consequently, a 
prevalence ratio cannot be calculated, and the values in the ‘Prevalence’ column for the placebo and AZ groups should be interpreted as ‘the percentage of 
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Table 4. The prevalence of azithromycin (AZ) and erythromycin (ERY) resistance in nasopharyngeal isolates of Streptococcus pneumoniae in Mali 
 
 




















Prevalence Ratio (95% 
CI) 
P-value 
Azithromycin Pre-2014 110 109 4 3.67 107 106 8 7.55      2.06 (0.64, 6.62) 0.227 
disc assay Post-2014 114 113 6 5.31 120 117 13 11.1      2.09 (0.81, 5.43) 0.129 
 Pre-2015 110 110 7 6.36 110 110 5 4.55       0.71 (0.23, 2.20) 0.558 
 Post-2015 143 143 4 2.80 134 134 10 7.46        2.67 (0.86, 8.27) 0.089 
 Pre-2016$ 49 34 8 23.5$ 54 40 8 20.0$          0.85 (0.36, 2.02) $ 0.713 
 Post-2016$ 94 81 25 30.9$ 61 54 37 68.5$ 2.22 (1.51, 3.27) $ <0.001 
 2018 188 180 31   17.2
$  165 152  29  19.1 $ 1.11(0.69, 1.77) $  0.669 
Azithromycin Pre-2014* 110 0 0 0.00* 107 2 2 100* NA   
E-test Post-2014* 114 6 6 100* 120 13 13 100* NA   
 Pre-2015* 110 7 7 100* 110 5 5 100* NA   
 Post-2015* 143 4 4 100* 134 11 11 100* NA   
 Pre-2016* 49 8 5 62.5* 54 8 5 62.5* NA  
 Post-2016* 94 25 17 68.0* 61 36 27 75.0* NA  
 2018 188 36 34 94.4*  165 29 29 100.0* NA  
Erythromycin Pre-2014 110 109 4 3.67 107 106 8 7.55        2.06 (0.64, 6.62) 0.227 
disc assay Post-2014 114 113 6 5.31 120 117 13 11.1           2.09 (0.81, 5.43) 0.129 
 Pre-2015 110 110 7 6.36 110 110 5 4.55        0.71 (0.23, 2.20) 0.558 
 Post-2015 143 143 4 2.80 134 134 12 8.96        3.20 (1.06, 9.65)  0.039 
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 Post-2016$ 94 81 23 28.4$ 61 53 35 66.0$ 2.33 (1.54, 3.51) $ <0.001 
 2018 188 180  27 15.0
$ 165 152 25 16.4 $ 1.10 (0.66, 1.83) $ 0.726 
 
$ In 2016 and 2018, not all positive samples were tested by disc assay; prevalences and prevalence ratios reflect the prevalence among those samples that were tested.  
*The azithromycin E-test was used only to confirm samples positive by the azithromycin disc assay, not to test all samples. Consequently, a prevalence ratio cannot be 
calculated, and the values in the ‘Prevalence’ column for the placebo and AZ groups should be interpreted as ‘the percentage of samples positive by disc assay that were 
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Table 5.  The prevalence of resistance in nasopharyngeal isolates of Streptococcus pneumoniae to penicillin and oxacillin in Burkina Faso and Mali 
  SMC + Placebo     SMC + Azithromycin   





















           
Oxacilllin Pre-2014 147 147 37 25.2 143 143 34 23.8 0.94 (0.63, 1.42) 0.783 
disc assay Post-2014 148 148 38 25.7 113 113 18 15.9 0.62 (0.37, 1.03) 0.064 
 Pre-2015 113 113 44 38.9 103 103 35 34.0 0.87 (0.61, 1.24) 0.452 
 Post-2015 143 143 44 30.8 124 124 33 26.6 0.86 (0.59, 1.26) 0.454 
 Pre-2016 103 103 39 37.9 96 96 27 28.1 0.74 (0.50, 1.11) 0.150 
 Post-2016 99 99 33 33.3 86 86 30 34.9 1.05 (0.70, 1.57) 0.826 
 2018 117 117 40 34.2 96 96 36 37.5 1.10 (0.76, 1.57) 0.616 
            
Penicillin Pre-2014 147 147 19 12.9 143 143 20 14.0 1.08 (0.60, 1.94) 0.791 
E-test Post-2014 148 148 21 14.2 113 113 16 14.2 1.00 (0.54, 1.84) 0.995 
 Pre-2015 113 113 5 4.4 103 103 6 5.8 1.32 (0.41, 4.20) 0.642 
 Post-2015 143 143 33 23.1 124 124 27 21.8 0.94 (0.60, 1.48) 0.799 
 Pre-2016 103 103 17 16.5 96 96 19 19.8 1.20 (0.66, 2.17) 0.549 
 Post-2016 99 99 11 11.1 86 86 12 14.0 1.26 (0.58, 2.70) 0.559 
 2018 117 117 29 24.8 96 96 26 27.1 1.09 (0.69, 1.73) 0.705 
Mali            
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disc sssay Post-2014 114 113 17 15.0 120 117 18 15.4 1.02 (0.55, 1.91) 0.944 
 Pre-2015 110 110 21 19.1 110 110 18 16.4 0.86 (0.49, 1.51) 0.596 
 Post-2015 143 143 32 22.4 134 134 18 13.4 0.60 (0.35, 1.02) 0.057 
 Pre-2016 49 34 15 44.1 54 40 11 27.5 0.62 (0.33, 1.18) 0.145 
 Post-2016 94 80 32 40.0 61 53 23 43.4 1.08 (0.73, 1.62) 0.692 












Figure 1. The prevalence of nasopharyngeal carriage of Streptococcus pneumoniae in three annual 
pre-and post-intervention surveys and one year after the last post-intervention survey  
(a) Burkina Faso 
 

















Figure 2. The prevalence of resistance to azithromycin among nasopharyngeal isolates of 
Streptococcus. pneumoniae in three annual pre-and post intervention surveys and one year after the 
last post-intervention survey was done (a) Burkina Faso and (b) Mali$.  Results from Disc Diffusion 
Assays. 
(a) Burkina Faso 
(b) Mali$
 
$ In Mali in 2016, not all positive samples were tested by disc assay; prevalences reflect the percentage 
positive among those samples that were tested.   
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